Andrew Reardon, Chief Legal Officer & Secretary, on June 01, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,135,316. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,382 common shares of the company, with 41,382 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/xslF345X05/edgardoc.xml
J. E. Davis, Director, Chief Executive Officer and President, on June 01, 2026, sold 10,000 shares in Quest Diagnostics (DGX) for $1,941,400. Following the Form 4 filing with the SEC, Davis has control over a total of 132,423 common shares of the company, with 132,423 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1022079/000159983726000005/xslF345X05/wk-form4_1780439916.xml
Christopher Peetz, Director, Chief Executive Officer, on June 01, 2026, sold 30,000 shares in Mirum Pharmaceuticals (MIRM) for $2,875,103. Following the Form 4 filing with the SEC, Peetz has control over a total of 381,809 common shares of the company, with 194,309 shares held directly and 187,500 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1759425/000161474026000010/xslF345X05/form4-06022026_070609.xml
Fariborz Assaderaghi, Executive Vice President, Engineering & Technology, on May 29, 2026, sold 1,500 shares in Sitime (SITM) for $1,069,080. Following the Form 4 filing with the SEC, Assaderaghi has control over a total of 79,936 common shares of the company, with 79,936 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1451809/000183467926000012/xslF345X05/wk-form4_1780447088.xml